Gwenn Hansen
2022
In 2022, Gwenn Hansen earned a total compensation of $3.8M as Chief Scientific Officer at Nurix Therapeutics, a 66% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $180,480 |
|---|---|
| Option Awards | $2,163,400 |
| Salary | $476,250 |
| Stock Awards | $999,993 |
| Other | $4,460 |
| Total | $3,824,583 |
Hansen received $2.2M in option awards, accounting for 57% of the total pay in 2022.
Hansen also received $180.5K in non-equity incentive plan, $476.3K in salary, $1M in stock awards and $4.5K in other compensation.
Rankings
In 2022, Gwenn Hansen's compensation ranked 913th out of 5,542 executives tracked by ExecPay. In other words, Hansen earned more than 83.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 913 out of 5,542 | 84th |
Division Manufacturing | 415 out of 3,000 | 86th |
Major group Chemicals And Allied Products | 146 out of 1,350 | 89th |
Industry group Drugs | 132 out of 1,253 | 90th |
Industry Pharmaceutical Preparations | 98 out of 907 | 89th |
Source: SEC filing on March 24, 2023.
Hansen's colleagues
We found two more compensation records of executives who worked with Gwenn Hansen at Nurix Therapeutics in 2022.
News
Nurix Therapeutics CEO Arthur Sands' 2023 pay falls 54% to $4.4M
March 27, 2024
Nurix Therapeutics CEO Arthur Sands' 2022 pay jumps 97% to $9.4M
March 24, 2023
Nurix Therapeutics COO Stefani Wolff receives $7.1M in 2021
March 25, 2022
Nurix Therapeutics CEO Arthur Sands' 2020 pay jumps 1,041% to $17M
March 25, 2021